Quantcast
Last updated on April 24, 2014 at 12:21 EDT

Latest Particle Sciences Inc. Stories

2014-02-04 12:28:09

BETHLEHEM, Pa., Feb. 4, 2014 /PRNewswire/ -- Particle Sciences, Inc. today announced the appointment of Robert Becker to the position of Vice President Biosciences Sales and Business Development. Dr. Becker, who holds a PhD in Microbiology and Immunology from the University of Kansas and an MBA from Columbia Business School, joins Particle Sciences following more than 24 years of experience in biopharmaceutical scientific and business leadership roles ranging from management of...

2014-01-28 12:30:05

BETHLEHEM, Pa., Jan. 28, 2014 /PRNewswire/ -- Particle Sciences, Inc. a drug delivery Contract Development and Manufacturing Organization (CDMO), has partnered with Hapten Sciences, Inc. to progress Hapten's lead product into the clinic. The product is a vaccine developed to lessen or eliminate contact dermatitis from Poison Ivy, Oak and Sumac exposure. According to Raymond Hage, CEO of Hapten, "Experts report that 50 to 85 percent of the population in the United States is sensitive...

2013-07-15 12:25:22

Innovative Software Automates Particle Location and Chemical Characterization EDISON, N.J., July 15, 2013 /PRNewswire/ -- HORIBA Scientific (HORIBA), the global leader in Raman spectroscopy systems, is proud to announce the launch of their new ParticleFinder module for the LabSpec 6 Spectroscopy Suite. ParticleFinder was developed as part of a collaboration with Particle Sciences, Bethlehem, PA, to support their client drug product formulation and analytic, bioanalytic, physical...

2013-03-05 12:29:28

BETHLEHEM, Pa., March 5, 2013 /PRNewswire/ -- Particle Sciences, a leading drug delivery CRO, has teamed up with NETZSCH Premier Technologies, a leading manufacturer of wet milling and dispersing equipment, to provide drug developers with improved access to state-of-the-art pharmaceutical nanomilling equipment and full pharmaceutical development capabilities. According to Robert Lee, PhD, Vice President Pharmaceutical Development, "Particle Sciences has been using particle size reduction -...

2013-01-08 12:26:40

BETHLEHEM, Pa., Jan. 8, 2013 /PRNewswire/ -- Particle Sciences, Inc. today announced the appointment of Deepak Tiwari, PhD to the position of Director, Formulation and Process Development. Dr. Tiwari, who holds a PhD in Pharmaceutical Sciences from St. John's University, joins Particle Sciences following more than 18 years' experience in pharmaceutical development roles. Most recently, he served as Director, Pharmaceutical Development at Agennix Inc. Prior to that, Dr. Tiwari held senior...

2012-06-06 06:26:41

BETHLEHEM, Pa., June 6, 2012 /PRNewswire/ -- Particle Sciences, a leading drug delivery CRO, has added new coating capabilities for preparing polymer film-based drug products from liquid formulations, under cGMPs. According to Garry Gwozdz, Director, Formulation Services, "Particle Sciences' purpose is to provide our clients with the most efficient drug product. Increasingly, we are seeing a demand for thin film-based products, particularly with respect to transdermal drug-eluting patch...

2012-03-21 06:25:11

BETHLEHEM, Pa., March 21, 2012 /PRNewswire/ -- Particle Sciences, Inc., a leading pharmaceutical CRO, today announced that it is developing with Pernix Therapeutics, a specialty pharmaceutical company, a new topical dermatology product for the pediatric market. Mark Mitchnick, CEO of Particle Sciences, said, "There are multiple treatments for many pediatric skin conditions. The unmet need is in the delivery of these agents via a more convenient, and improved vehicle. Particle...

2012-03-05 12:25:00

BETHLEHEM, Pa., March 5, 2012 /PRNewswire/ -- Particle Sciences, Inc. (PSI), a leading pharmaceutical CRO, and Lyotropic Therapeutics, Inc. (LTI), a drug delivery technology company, announced today that Particle Sciences has acquired the exclusive rights to Lyotropic's LyoCell® patent portfolio. The LyoCell technology allows for the solubilization, stabilization, and delivery of a wide range of compounds - both small and large molecule. According to Robert Lee, Particle Sciences' VP...

2012-02-16 12:00:00

BETHLEHEM, Pa., Feb. 16, 2012 /PRNewswire/ -- Particle Sciences, Inc. (PSI), a leading pharmaceutical CRO, announced today that Robert Gwozdz, M.S. Pharmaceutics, will now be heading PSI's oral formulation efforts. According to Mark Mitchnick, the company's CEO, "PSI has a broad array of drug delivery technologies applicable across many dosage forms and drug types. For instance, about 70% of our work now is on small molecules of which about 80% fall into BCS II. About 25% of our work is on...

2012-02-09 12:05:00

BETHLEHEM, Pa., Feb. 9, 2012 /PRNewswire/ -- Particle Sciences Inc. (PSI), a leading pharmaceutical CRO, and CHEMO, a multinational and pharmaceutical company with strong industrial capacities for APIs and Finished-Dosage-Forms (FDF), have formed a partnership to offer complete contract product development and commercial manufacturing of hormone-eluting devices. Particle Sciences is a world leader in the formulation, testing and scale up drug/device combinations and has been...